HOUSTON – The U.S. Food and Drug Administration has fast-tracked a promising drug to treat COVID-19 patients and it is in trial at Houston Methodist Hospital.
The drug is called RLF-100 and is also known as aviptadil. It has been approved by the FDA for emergency use at multiple clinical sites in patients who are too ill to enter the FDA’s Phase 2/3 trials.
According to a press release from the drug maker NeuroRX, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes.
The drug has been successful in reducing lung inflammation and so the FDA now says any doctor at any hospital can request this treatment to help severely ill COVID-19 patients.
To learn more about the RLF-100, click here.